Compare Pacific Gas & Electric Co. Common Stock (PCG) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pacific Gas & Electric Co. Common Stock vs Tango Therapeutics Inc. — how do they compare? Pacific Gas & Electric Co. Common Stock trades at $13.26 (market cap $39.48B), while Tango Therapeutics Inc. trades at $22.3 (market cap $3.74B). The key difference: Pacific Gas & Electric Co. Common Stock is far larger — about 10.6× Tango Therapeutics Inc.'s market cap, and Pacific Gas & Electric Co. Common Stock pays a 1.52% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Pacific Gas & Electric Co. Common Stock for 6 Days and Tango Therapeutics Inc. for 0 Days on average.
| PCG | TNGX | |
|---|---|---|
Market Cap | $39.48B | $3.74B |
Volume | 21,532,932 | 3,438,781 |
Sector | Utilities | Health |
52-Week High | $19.11 | $32.90 |
52-Week Low | $11.95 | $7.50 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $104.79B | $2.76B |
Dividend Yield | 1.52% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PCG trades at $13.33, up 1.29% with a bullish technical signal despite mixed momentum indicators. The stock shows strong fundamentals with a P/E of 9.59 and net income margin of 12.25%, supported by recent earnings beats. Recent news highlights PG&E's proactive wildfire safety measures and strategic initiatives, including a 10-year undergrounding plan to mitigate risks. Analyst consensus remains positive with a $18.22 price target, though technical indicators show some overbought conditions.
PCG presents a value opportunity with attractive valuation metrics and improving profitability, but faces significant wildfire-related risks and regulatory uncertainty. The stock's upside potential depends on successful execution of safety initiatives and favorable regulatory outcomes, making it suitable for risk-tolerant investors seeking utility exposure with growth potential.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Pacific Gas & Electric Co. Common Stock
PG&E Corporation is the parent company of Pacific Gas and Electric Company, a utility serving Northern and Central California. Its main business is the sale and delivery of electricity and natural gas.
Read more on PCG →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
